Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern

19 May 2024

Abstract excerpt

The emergence and ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has highlighted the need for rapid vaccine development platforms that can be updated to counteract emerging variants of currently circulating and future emerging coronaviruses. Here we report the development of a "train model" subunit vaccine platform that contains a SARS-CoV-2 Wuhan S1 protein (the "engine")...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Vaccine Coverage and Hesitancy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38769033
DOI: 10.1016/j.vaccine.2024.05.028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernPMID 38769033Read ↗

Efficacy of a stable multivalent broadly protective subunit vaccine platform against SARS-CoV-2 variants of concernSemantic proximity Read ↗

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity Read ↗

Challenges and developments in universal vaccine design against SARS-CoV-2 variantsSemantic proximity Read ↗

Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™.Semantic proximity Read ↗

Protection of Hamsters Challenged with SARS-CoV-2 after Two Doses of MVC-COV1901 Vaccine Followed by a Single Intranasal Booster with Nanoemulsion Adjuvanted S-2P VaccineSemantic proximity Read ↗

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity Read ↗

Immunogenicity and in vivo protective effects of recombinant nucleocapsid-based SARS-CoV-2 vaccine Convacell®Semantic proximity Read ↗

A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variantsSemantic proximity Read ↗

A Beta-containing bivalent SARS-CoV-2 spike protein vaccine candidate with AS03 elicits durable and broad neutralization of variants including Omicron in macaques and confers protection in hamstersSemantic proximity Read ↗

Immunogenicity and pre-clinical efficacy of an OMV-based SARS-CoV-2 vaccineSemantic proximity Read ↗

Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum ProtectionSemantic proximity Read ↗

Immunogenicity and In vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.